Cefaclor
Second-Generation Cephalosporins
- Drug class
- Second-Generation Cephalosporins
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 12
- FDA reports (12 mo)
- 82
Overview
Plain-language summary, compiled from the cited regulatory records
Cefaclor is an antibiotic medication belonging to the second-generation cephalosporin class of drugs [1]. It is approved for use in treating or preventing infections that are known or strongly suspected to be caused by bacteria susceptible to cefaclor [1]. The selection or modification of antibacterial therapy should consider available culture and susceptibility information [1].
Cefaclor is available under various brand names. In the past 12 months, there have been 82 adverse event reports associated with cefaclor [2]. The most frequently reported adverse events include off-label use, anemia, drug ineffectiveness, drug hypersensitivity, and pyrexia [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 11 | April 17, 2026 |
| US United States | FDA | 1 | July 31, 2019 |
GBUnited Kingdom· MHRA
11 products
Uses
Cefaclor is indicated for the treatment of the following infections due to susceptible micro-organisms: • Respiratory tract infections, including pneumonia, bronchitis, exacerbations of chronic bronchitis, pharyngitis and tonsillitis, and as part of the management of sinusitis.
• Otitis media. • Skin and soft tissue infections. • Urinary tract infections, including pyelonephritis and cystitis. • Cefaclor has been found to be effective in both acute and chronic urinary tract infections. • Cefaclor is generally effective in the eradication of streptococci from the nasopharynx, but data establishing efficacy in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available.
How to take
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms.
Drug interactions
Known interactions involving Cefaclor. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL517180004 · revised January 24, 2025
- [2]FDA DailyMed · 0878bdc2-0410-49… · revised July 31, 2019 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.